Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MMX mesalamine remission maintenance study in ulcerative colitis
2009-017044-13Phase 4Completed
- Sponsor
- Takeda
- Start
- Mar 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of Salcrozine in autoimmune colitis (2 arms), sponsored by Takeda. Primary endpoint: Complete remission at 12 months. Started Mar 2010; status: completed.
02
Drugs
Salcrozine
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2009-017044-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-017044-13.